Summary

The Randomized Olmesartan And Diabetes MicroAlbuminuria Prevention [ROADMAP; NCT00185159] study investigated whether early administration of an angiotensin receptor blocker to diabetic patients with normal albumin excretion could delay or prevent the first occurrence of microalbuminuria and whether it could affect the incidence of cardiovascular and renal events.